JHP Pharmaceuticals to Produce Injectable for Cardiovascular Use
Contract manufacturer JHP Pharmaceuticals has entered into an agreement with a pharmaceutical company to produce clinical and commercial supply of an innovative injectable used in the cardiovascular setting, the company reported in a press release.
"We are pleased to serve this important customer and recognize that being selected to produce this injectable is based on our expertise with complex formulations coupled with our competence in both clinical supply and commercial supply," said Stuart Hinchen, president and CEO of JHP, in the release. "JHP's extensive experience working with products through their life cycle starting with clinical trials through approval, product launch and global commercialization provides customers with a measure of confidence allowing them to focus on their day-to-day business priorities."
Headquartered in New Jersey, JHP Pharmaceuticals provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. Its sterile manufacturing facility is located in Rochester, MI, and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, a clinical filling line, and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.
For more information, please visit www.jhppharma.com.